Skip to content

Author

Daniel Weintraub

We have 7 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Association between self-reported physical activity levels and patient reported cognitive problems in Parkinson's disease

Background Cognitive dysfunction is a highly impactful symptom experienced by some people with Parkinson's disease (PD). Physical activity may slow cognitive impairment in PD. Objective Evaluate associations between self-reported physical activity and prevalence and incidence of bothersome cognitive problems, as measur...

A. Amara, J. Purks, Connie Marras et al. · 0 citations
Open access Oct 2026

Neuropsychiatric and Cognitive Symptom Evolution over the First Decade of Biomarker-Positive, Sporadic Parkinson's Disease.

BACKGROUND Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co-occur. Their long-term evolution remains incompletely characterized, particularly in biomarker-positive cohorts. OBJECTIVE The aim was to examine the evolut...

Izabelle Schoen, Jing Wang, Sharon X. Xie et al. · 0 citations
Review Open access Sep 2026

Update on Parkinson's Disease Psychosis: Epidemiology, Mechanisms and Management.

Psychosis in Parkinson's disease (PD) is a common and debilitating non-motor symptom that can occur at any stage of the disease. PD psychosis (PDP) manifests as a diverse clinical spectrum that can include misperceptions, passage and presence phenomena, hallucinations, and delusions, alone or in combination. This revie...

Caroline Kruse, Daniel Weintraub, John E. Duda et al. · 0 citations
Review Open access Aug 2026

Apathy in Lewy Body Disorders: A Position Paper.

Apathy is one of the most prevalent and disabling non-motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional ou...

J. Kulisevsky, Lidia Bojtos, M. Kramberger et al. · 1 citation
Review Open access Aug 2026

Meditation and breathwork on anxiety in Parkinson's disease: A pilot randomized controlled trial

Remotely-delivered meditation and breathwork through the BSM program significantly reduced anxiety in individuals with Parkinson's Disease in the authors' study and may be a promising non-pharmacological therapy.

Akila Rayapuraju, P. U. Reed, Jennifer Liu et al. · 1 citation
Review Open access Sep 2026

Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development

Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.

Chris J. Edgar, Kathleen L. Poston, Cheryl D. Coon et al. · 0 citations
Open access Sep 2026

Utilizing intraindividual cognitive variability to predict progression in stage 2 neuronal synuclein disease.

OBJECTIVE Neuronal synuclein disease (NSD) involves pathological α-synuclein presence and often dopaminergic dysfunction, initially preceding overt clinical symptoms. NSD-Integrated Staging System identifies Stage 2A (no dopaminergic dysfunction) and 2B (dopaminergic dysfunction) as prodromal phases marked by subtle cl...

Hannah L. Combs, R. Kurth, A. Nair et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.